Novartis Heart Drug Failure Throws Key Pipeline Catalyst into Doubt

What happened

Novartis announced that its investigational heart drug targeting genetically elevated Lp(a) (pelacarsen) failed to meet its primary endpoint in the Phase III HORIZON outcomes trial, a major setback for a key pipeline catalyst. This failure leaves doctors without evidence that lowering Lp(a) improves cardiovascular outcomes, undermining a potential multibillion-dollar opportunity and sending the stock lower. The DeepValue master report had flagged pelacarsen as the largest non-oncology pipeline event in the valuation debate, making this news materially negative for the investment thesis. While Novartis still has Pluvicto mHSPC approval and other catalysts, the loss of pelacarsen reduces the upside optionality that supported the premium multiple. The stock is likely to de-rate as the market reassesses the balance of pipeline risk against ongoing pressure from Entresto generic erosion and margin compression.

Implication

The pelacarsen failure materially weakens the near-term catalyst story, shifting the risk/reward toward the bear scenario with implied value near $128. Management's ability to offset Entresto erosion with new launches now depends almost entirely on Pluvicto approval and uptake, which is not yet guaranteed and carries execution risk. The remaining H2 readouts (remibrutinib MS, del-desiran) are lower probability and do not compensate for the loss of pelacarsen's large addressable market. With net debt rising and operating margins under pressure, the balance-sheet cushion is thinner, and downside protection is less robust. Investors should wait for sub-$140 entry or clear signs that other catalysts are succeeding before committing capital, and should reassess the bear case probability upward from 30%.

Thesis delta

The failure of pelacarsen removes a key pillar of the bull case and increases the probability of the bear scenario. The WAIT rating becomes more precarious, and the attractive entry level may need to be lowered further. Investors should re-evaluate the remaining catalysts with lower conviction until there is evidence that Pluvicto and other programs can compensate for the lost pipeline opportunity.